BioSpace News Archive

The invention provides a more comfortable way for a pregnant woman to sleep on her stomach.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc.

The Woodlands at Furman is celebrating its 10-year anniversary this month. Upstate South Carolina’s only locally-owned, nonprofit Life Care community opened in 2009.

Avion Pharmaceuticals, LLC., a women’s health pharmaceutical company, is partnering with Miesha Tate, a former UFC and MMA champion, to bring greater awareness to the importance of prenatal care and education.

Orbita, Inc., provider of the onlyHIPAA-compliant platform for voice and chatbot applications in healthcare, today announced through its collaboration with Mayo Clinic, the availability of Mayo Clinic’s award-winning first-aid voice application on two additional platforms: Google Assistant and voice-powered web chat.

Haselmeier is a leading solution provider for self-injection devices. As an innovative and strategic partner for pharmaceutical and biotechnology companies, Haselmeier develops and produces customized, unique self-injection systems that are used worldwide

Chemspace and LabNetwork, a WuXi AppTec company, both online marketplaces for chemical compounds used in drug discovery, today announced they have entered into a collaboration agreement

Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announces new data supporting the immunotherapeutic blockade of Clever-1 as an alternative to, or in combination with, PD-1 checkpoint inhibition to reactivate immunity against immunosuppressive tumours.

Dornier MedTech (Dornier), pioneer in creating extracorporeal shockwave technology for urological and orthopedic indications, today announced the presentation of new data from two clinical studies on low-intensity shockwaves (LiST) as a treatment for Erectile Dysfunction (ED) at the 21st Congress of the European Society of Sexual Medicine taking place in Ljubljana, Slovenia on 14 – 16 February 2019.

Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018.